ID   VOA4627
AC   CVCL_VQ38
SY   VOA-4627
DR   cancercelllines; CVCL_VQ38
DR   Wikidata; Q98134551
RX   DOI=10.14288/1.0319145;
RX   PubMed=27822414;
RX   PubMed=28545687;
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Heterozygous (PubMed=27822414).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Heterozygous (PubMed=27822414).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (PubMed=27822414).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=27822414
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 8,10
ST   D21S11: 30
ST   D5S818: 13
ST   D7S820: 11
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 15,17
DI   NCIt; C105556; Low grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VQ43 ! VOA4698
OI   CVCL_VQ51 ! VOA4881
OI   CVCL_VQ39 ! VOA5646
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 8
//
RX   DOI=10.14288/1.0319145;
RA   Dawson A.;
RT   "Targeted therapy in low-grade serous ovarian carcinoma:
RT   characterization of MEK inhibitor response in novel patient-derived
RT   cell lines.";
RL   Thesis PhD (2016); University of British Columbia; Vancouver; Canada.
//
RX   PubMed=27822414; PMCID=PMC5088288;
RA   Fernandez M.L., DiMattia G.E., Dawson A., Bamford S., Anderson S.,
RA   Hennessy B.T., Anglesio M.S., Shepherd T.G., Salamanca C.M.,
RA   Hoenisch J., Tinker A., Huntsman D.G., Carey M.S.;
RT   "Differences in MEK inhibitor efficacy in molecularly characterized
RT   low-grade serous ovarian cancer cell lines.";
RL   Am. J. Cancer Res. 6:2235-2251(2016).
//
RX   PubMed=28545687; DOI=10.1016/j.ygyno.2017.05.019;
RA   Mert I., Chhina J., Allo G., Dai J., Seward S., Carey M.S.,
RA   Llaurado M., Giri S., Rattan R., Munkarah A.R.;
RT   "Synergistic effect of MEK inhibitor and metformin combination in low
RT   grade serous ovarian cancer.";
RL   Gynecol. Oncol. 146:319-326(2017).
//